STRONG-HF Risk Framework Calculator

Clinical calculation support · Verify results before clinical use

Important clinical limitation. The point weights and thresholds in this prototype have not been validated or calibrated against patient outcomes. The total must not be interpreted as an absolute 180-day risk, used to make treatment decisions, or substituted for clinical assessment and validated prediction tools.

Patient parameters

Enter values from the relevant clinical assessment.

9 inputs
Use the percentage definition intended by your local protocol; the prototype does not define a validated composite GDMT-dose metric.
Reset

About this framework

This page implements a transparent, manually specified points prototype using age, haemodynamics, NT-proBNP, renal function, potassium, LVEF, prior HF hospitalization, and the reported percentage of guideline-directed medical therapy (GDMT) dose achieved at discharge.

It is not an equation derived from the STRONG-HF trial. The variables, point weights, thresholds, and total-score interpretation have not been established as a validated model for predicting an individual's 180-day risk of death or HF readmission.

Prototype scoring rules

VariableRulePoints
Age65–74 years / ≥75 years+1 / +2
SBP<100 mmHg+2
Heart rate>100 bpm+1
NT-proBNP>1000–2000 / >2000–4000 / >4000 pg/mL+1 / +2 / +3
eGFR<45 / <30 mL/min/1.73 m²+1 / +2
Potassium>5.0 mmol/L+1
LVEF<40%+1
Prior HF hospitalizationWithin 12 months+3
GDMT dose achieved<50% / 50–<90%+2 / +1

Clinical context

STRONG-HF evaluated a high-intensity care strategy involving rapid GDMT up-titration and close post-discharge follow-up, with monitoring of clinical status, laboratory values, and NT-proBNP. Trial eligibility and protocol safety criteria are not interchangeable with a prognostic score. Medication titration should follow clinical assessment, contraindications, and applicable guideline recommendations.

References

Mebazaa A, et al. STRONG-HF randomized trial.

Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. The Lancet. 2022;400(10367):1938–1952.

doi:10.1016/S0140-6736(22)02076-1
PubMed: 36356631
STRONG-HF trial registration.

ClinicalTrials.gov. Safety, Tolerability, and Efficacy of Rapid Optimization, Helped by NT-proBNP Testing of Heart Failure Therapies.

NCT03412201 — official trial record
STRONG-HF safety indicators analysis.

Safety Indicators in Patients Receiving High-intensity Care After Hospital Admission for Acute Heart Failure: The STRONG-HF Trial.

PubMed: 37820896
Clinical disclaimer: This prototype is for education and software demonstration only. It is not validated for diagnosis, prognosis, treatment selection, discharge decisions, or individual risk estimation. A numerical total does not establish a patient's absolute risk. Use clinical judgement and validated instruments when indicated; assess concerning haemodynamic or laboratory findings directly and urgently when clinically appropriate.